Avrion Therapeutics
Company Details
Status: Private
Employees: 1-10
Location:
Allschwil, Basel-Country, Switzerland
Type:
sample
Technology:
sample
sample
About: Founded in 2020, based on 10+ years of research at the Swiss Federal Institute of Technology EPFL Brain Mind Institute and Bertarelli Foundation Gene Therapy Platform, Avrion Therapeutics targets genetically-linked neurodegenerative diseases using precision gene therapy to enable long-term solutions. Avrion has developed a first-in-class precision gene therapy platform to selectively and safely target discrete cells in the brain including neurons and astrocytes. This therapeutic platform is supported by a preclinical discovery engine to identify novel targets to treat neurodegenerative diseases with unmet medical need. Avrions’ first clinical candidate gene therapy product, AVR-001, is preparing to enter IND-enabling studies to treat patients with a form of motor neuron disease (amyotrophic lateral sclerosis - ALS), a fatal neuromuscular disorder.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Avrion Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.